Under this hypothesized scheme, CXCL10 and CXCL13, B-cell and Ig deposition, L-selectin and CD30/CD153 [47] could represent candidate target points in the therapy of LMP1-expressing carcinomas, as well as more generally skin carcinomas and certain inflammatory conditions, such as atopic dermatitis showing similar pathological features. The gene discussed is SELL; the disease is skin carcinoma.